Shree Ganesh Remedies Ltd — Important, 23-01-2026: Company Update

Shree Ganesh Remedies has released its financial results for the quarter and nine months. For Q3, revenue from operations declined 22% year-on-year to ₹21.11 Cr, with EBITDA falling 32% to ₹6.73 Cr and PAT decreasing 43% to ₹3.10 Cr. Management cited shipment delays, deferring 10-12% of topline to Q4, challenging European demand, and heightened competition as key factors. Operationally, a new pilot facility is commissioned, and the Block 7 expansion for commercial production is on track for H1FY27. Its CRAMS engagement with a Japanese client is also advancing. The company anticipates gradual business improvement in FY27, driven by increased new product development and CRAMS business traction.